Literature DB >> 24516010

Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery.

Nicholas F Marko1, Robert J Weil, Jason L Schroeder, Frederick F Lang, Dima Suki, Raymond E Sawaya.   

Abstract

PURPOSE: Approximately 12,000 glioblastomas are diagnosed annually in the United States. The median survival rate for this disease is 12 months, but individual survival rates can vary with patient-specific factors, including extent of surgical resection (EOR). The goal of our investigation is to develop a reliable strategy for personalized survival prediction and for quantifying the relationship between survival, EOR, and adjuvant chemoradiotherapy. PATIENTS AND METHODS: We used accelerated failure time (AFT) modeling using data from 721 newly diagnosed patients with glioblastoma (from 1993 to 2010) to model the factors affecting individualized survival after surgical resection, and we used the model to construct probabilistic, patient-specific tools for survival prediction. We validated this model with independent data from 109 patients from a second institution.
RESULTS: AFT modeling using age, Karnofsky performance score, EOR, and adjuvant chemoradiotherapy produced a continuous, nonlinear, multivariable survival model for glioblastoma. The median personalized predictive error was 4.37 months, representing a more than 20% improvement over current methods. Subsequent model-based calculations yield patient-specific predictions of the incremental effects of EOR and adjuvant therapy on survival.
CONCLUSION: Nonlinear, multivariable AFT modeling outperforms current methods for estimating individual survival after glioblastoma resection. The model produces personalized survival curves and quantifies the relationship between variables modulating patient-specific survival. This approach provides comprehensive, personalized, probabilistic, and clinically relevant information regarding the anticipated course of disease, the overall prognosis, and the patient-specific influence of EOR and adjuvant chemoradiotherapy. The continuous, nonlinear relationship identified between expected median survival and EOR argues against a surgical management strategy based on rigid EOR thresholds and instead provides the first explicit evidence supporting a maximum safe resection approach to glioblastoma surgery.

Entities:  

Mesh:

Year:  2014        PMID: 24516010      PMCID: PMC4876349          DOI: 10.1200/JCO.2013.51.8886

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  11 in total

1.  Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma.

Authors:  G Evren Keles; Edward F Chang; Kathleen R Lamborn; Tarik Tihan; Chih-Ju Chang; Susan M Chang; Mitchel S Berger
Journal:  J Neurosurg       Date:  2006-07       Impact factor: 5.115

Review 2.  Extent of resection influences outcomes for patients with gliomas.

Authors:  N Sanai; M S Berger
Journal:  Rev Neurol (Paris)       Date:  2011-09-07       Impact factor: 2.607

3.  Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.

Authors:  René-Olivier Mirimanoff; Thierry Gorlia; Warren Mason; Martin J Van den Bent; Rolf-Dieter Kortmann; Barbara Fisher; Michele Reni; Alba A Brandes; Jüergen Curschmann; Salvador Villa; Gregory Cairncross; Anouk Allgeier; Denis Lacombe; Roger Stupp
Journal:  J Clin Oncol       Date:  2006-06-01       Impact factor: 44.544

Review 4.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

Authors:  Therese A Dolecek; Jennifer M Propp; Nancy E Stroup; Carol Kruchko
Journal:  Neuro Oncol       Date:  2012-11       Impact factor: 12.300

5.  MR imaging correlates of survival in patients with high-grade gliomas.

Authors:  Whitney B Pope; James Sayre; Alla Perlina; J Pablo Villablanca; Paul S Mischel; Timothy F Cloughesy
Journal:  AJNR Am J Neuroradiol       Date:  2005 Nov-Dec       Impact factor: 3.825

6.  An extent of resection threshold for newly diagnosed glioblastomas.

Authors:  Nader Sanai; Mei-Yin Polley; Michael W McDermott; Andrew T Parsa; Mitchel S Berger
Journal:  J Neurosurg       Date:  2011-03-18       Impact factor: 5.115

7.  The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere.

Authors:  G E Keles; B Anderson; M S Berger
Journal:  Surg Neurol       Date:  1999-10

8.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

Review 9.  Glioma extent of resection and its impact on patient outcome.

Authors:  Nader Sanai; Mitchel S Berger
Journal:  Neurosurgery       Date:  2008-04       Impact factor: 4.654

10.  The value of glioma extent of resection in the modern neurosurgical era.

Authors:  Douglas A Hardesty; Nader Sanai
Journal:  Front Neurol       Date:  2012-10-18       Impact factor: 4.003

View more
  85 in total

1.  The patients' view: impact of the extent of resection, intraoperative imaging, and awake surgery on health-related quality of life in high-grade glioma patients-results of a multicenter cross-sectional study.

Authors:  Katrin Nickel; Mirjam Renovanz; Jochem König; Linda Stöckelmaier; Anne-Katrin Hickmann; Minou Nadji-Ohl; Jens Engelke; Elke Weimann; Dirk Freudenstein; Oliver Ganslandt; Lars Bullinger; Christian Rainer Wirtz; Jan Coburger
Journal:  Neurosurg Rev       Date:  2017-03-06       Impact factor: 3.042

2.  Minimally invasive resection of intracranial lesions using tubular retractors: a large, multi-surgeon, multi-institutional series.

Authors:  Daniel G Eichberg; Long Di; Ashish H Shah; Evan M Luther; Christina Jackson; Lina Marenco-Hillembrand; Kaisorn L Chaichana; Michael E Ivan; Robert M Starke; Ricardo J Komotar
Journal:  J Neurooncol       Date:  2020-06-18       Impact factor: 4.130

Review 3.  Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.

Authors:  Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

4.  The impact of 5-aminolevulinic acid on extent of resection in newly diagnosed high grade gliomas: a systematic review and single institutional experience.

Authors:  Sameah A Haider; Seokchun Lim; Steven N Kalkanis; Ian Y Lee
Journal:  J Neurooncol       Date:  2018-12-01       Impact factor: 4.130

Review 5.  Genetic and molecular epidemiology of adult diffuse glioma.

Authors:  Annette M Molinaro; Jennie W Taylor; John K Wiencke; Margaret R Wrensch
Journal:  Nat Rev Neurol       Date:  2019-06-21       Impact factor: 42.937

Review 6.  Overcoming therapeutic resistance in glioblastoma: the way forward.

Authors:  Satoru Osuka; Erwin G Van Meir
Journal:  J Clin Invest       Date:  2017-02-01       Impact factor: 14.808

Review 7.  Fluorescent-Guided Surgical Resection of Glioma with Targeted Molecular Imaging Agents: A Literature Review.

Authors:  Sonya E L Craig; James Wright; Andrew E Sloan; Susann M Brady-Kalnay
Journal:  World Neurosurg       Date:  2016-02-23       Impact factor: 2.104

8.  Recurrent glioblastomas in the elderly after maximal first-line treatment: does preserved overall condition warrant a maximal second-line treatment?

Authors:  Marc Zanello; Alexandre Roux; Renata Ursu; Sophie Peeters; Luc Bauchet; Georges Noel; Jacques Guyotat; Pierre-Jean Le Reste; Thierry Faillot; Fabien Litre; Nicolas Desse; Evelyne Emery; Antoine Petit; Johann Peltier; Jimmy Voirin; François Caire; Jean-Luc Barat; Jean-Rodolphe Vignes; Philippe Menei; Olivier Langlois; Edouard Dezamis; Antoine Carpentier; Phong Dam Hieu; Philippe Metellus; Johan Pallud
Journal:  J Neurooncol       Date:  2017-07-19       Impact factor: 4.130

9.  The influence of preoperative dependency on mortality, functional recovery and complications after microsurgical resection of intracranial tumors.

Authors:  Martin N Stienen; David Y Zhang; Morgan Broggi; Dominik Seggewiss; Stefano Villa; Silvia Schiavolin; Oliver Bozinov; Niklaus Krayenbühl; Johannes Sarnthein; Paolo Ferroli; Luca Regli
Journal:  J Neurooncol       Date:  2018-05-02       Impact factor: 4.130

10.  Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor.

Authors:  Takuya Toyonaga; Shigeru Yamaguchi; Kenji Hirata; Kentaro Kobayashi; Osamu Manabe; Shiro Watanabe; Shunsuke Terasaka; Hiroyuki Kobayashi; Naoya Hattori; Tohru Shiga; Yuji Kuge; Shinya Tanaka; Yoichi M Ito; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-10-18       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.